What Biotechs Can Learn From Banking Scandals

Theranos, the former high-flying biotech startup, has recently had to tell regulators that it was voiding two years of tests from its Edison blood testing devices. This scandal could lead to a lack of public trust in new technology from healthcare start-ups. After all, how can a company with a high profile CEO, high valuation and well-known board members get things so wrong ? Similar questions were asked about banks after the financial crash in 2008 and they have still not regained public trust.